Comparative studies on novel combinations of pregabalin plus venlafaxine with standard diazepam and marketed combination of alprazolam plus sertraline for anxiety disorders
Vol 6, Issue 1, 2023
VIEWS - 2218 (Abstract) 480 (PDF)
Abstract
Summary Objective- In present study, eleven novel dose combinations of Pregabalin & Venlafaxine from minimum effective dose to higher anxiolytic dose were taken for assessment of anxiolytic activity in Swiss mice.
Method — Classical animal models of anxiety vise: Elevated plus-maze model and Light & Dark Exploration test Apparatus. Diazepam was used as a standard anxiolytic. In addition the combinations were also compared with a fixed dose marketed combination of Alprazolam & Sertraline (Anxit Plus).
Result — The results of the study reveal that combinations of Pregabalin & Venlafaxine (serotonin norepinephrine reuptake inhibitor) have better anxiolytic efficacy, which is comparable to Diazepam and Alprazolam-Sertraline combination.
Conclusion- Further clinical studies are required for getting better idea about efficacy and clinical utility of Pregabalin-Venlafaxine combination.
Keywords
Full Text:
PDFReferences
1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6):593-602.
2. Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 2006; 67: 20-26.
3. Davidson JR. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry. 2009; 70: 25-31.
4. Westenberg HG. Recent advances in understanding and treating social anxiety disorder. CNS Spectr. 2009; 14(2): 24-33.
5. Gupta YK, Prakash A. Therapeutic potential of 5-HT receptor modulators. Ind J Pharmacol. 1994; 26: 94-107.
6. Lee SI, Keltner NL. Serotonin and norepinephrine reuptake inhibitors (SNRIs): Venlafaxine and Duloxetine. Perspect. Psychi. Care. 2006.
7. Driot D, Bismuth M, Maurel A, Soulie-Albouy J, Birebent J, Oustric S, Dupouy J. Management of first depression or generalized anxiety disorder episode in adults in primary care: A systematic metareview. Presse Med. 2017; 46(12): 1124-1138.
8. Paul JW. GABA-A receptors: a viable target for novel anxiolytics? Curr Opin Pharmacol. 2006; 6: 24-29.
9. Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014; 28(9):835-54.
10. Parker L, Huelin R, Khankhel Z, Wasiak R, Mould J. A systematic review of pharmacoeconomic studies for pregabalin. Pain Pract. 2015; 15(1):82-94.
11. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995; 49(2):280-94.
12. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985; 14: 149-167.
13. Rodgers RJ, Shepherd JK. Influence of prior maze experience on behavior and response to diazepam in the elevated plus-maze and light/ dark tests of anxiety in mice. Psychopharmacology (Berl). 1993; 113: 237-242.
14. Hascoet M. Bourin A. New approach to Light/Dark test procedure in mice. Pharmacol Biochem Behav. 1998; 60(3): 645-653.
15. Bourin M, Hascoet M. The mouse light/dark box test. Eur J Pharmacol. 2003; 463: 55-65.
16. Gaurav Patki, Lumeng Li, Farida Allam, Naimesh Solanki, An T Dao, Karim Alkadhi, and Samina Salim, Moderate treadmill exercise rescues anxiety and depression-like behavior as well as memory impairment in a rat model of posttraumatic stress disorder. Physiol Behav. 2014; 130: 47–53.
DOI: https://doi.org/10.24294/as.v1i3.977
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This site is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.